Hope for patients with intracerebral hemorrhage
Bioxodes closes €12 million in Series A funding round
30-Nov-2023 -
Bioxodes SA, a biopharmaceutical company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces €12million ($13M) in a SeriesA funding from historic investors. This financial backing includes €8.6million ($9.3M) in ...
clinical development
drug candidates
inflammatory diseases
+2